Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
North Carolina Reaches $11 Million EpiPen Settlement Over Pricing Practices
05/06/2026
Grace Taylor, MS, MA
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11...
05/06/2026
Pharmacy Learning Network
PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
PharmLaw
Drug Lobby Challenges Washington State 340B Pharmacy Law
04/27/2026
Grace Taylor, MS, MA
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade...
04/27/2026
Pharmacy Learning Network
PharmLaw
Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health
04/21/2026
Hannah Musick
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs...
04/21/2026
Pharmacy Learning Network
PharmLaw
CMS Proposes Sweeping Prior Authorization Reforms for Drugs, Expanding Transparency and Electronic Requirements
04/15/2026
Hannah Musick
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare &...
04/15/2026
Pharmacy Learning Network

FDA Recalls

News
Duloxetine Delayed-Release Capsules Recalled Due to CGMP Deviations
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
Enalapril Maleate Tablets Recalled Due to Failed Impurities/Degradation Specifications
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
Naproxen Oral Suspension Recalled Due to Chemical Contamination
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for naproxen oral suspension due to excessive amounts of lead and lithium.
The US Food and Drug Administration (FDA) has issued a Class II recall for naproxen oral suspension due to excessive amounts of lead and lithium.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
FDA Issues Class II Recall for Peritoneal Dialysis Solutions Due to Potential Sterility Breach
05/07/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for Fresenius DELFLEX peritoneal dialysis solutions due to potential bag leaks compromising sterility, affecting more than 80 000 units used in renal care.
The US Food and Drug Administration (FDA) has issued a Class II recall for Fresenius DELFLEX peritoneal dialysis solutions due to potential bag leaks compromising sterility, affecting more than 80 000 units used in renal care.
The US Food and Drug...
05/07/2026
Pharmacy Learning Network
News
Lubricant Eye Drops Under Class II Recall for Sterility Concerns
05/07/2026
Hannah Musick
A class II recall has been issued for FRESHKOTE Lubricant Eye Drops due to sterility assurance concerns, affecting more than 50 000 units used for dry eye relief.
A class II recall has been issued for FRESHKOTE Lubricant Eye Drops due to sterility assurance concerns, affecting more than 50 000 units used for dry eye relief.
A class II recall has been...
05/07/2026
Pharmacy Learning Network

In the News

News
Duloxetine Delayed-Release Capsules Recalled Due to CGMP Deviations
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
Enalapril Maleate Tablets Recalled Due to Failed Impurities/Degradation Specifications
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
Naproxen Oral Suspension Recalled Due to Chemical Contamination
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for naproxen oral suspension due to excessive amounts of lead and lithium.
The US Food and Drug Administration (FDA) has issued a Class II recall for naproxen oral suspension due to excessive amounts of lead and lithium.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
FDA Issues Class II Recall for Peritoneal Dialysis Solutions Due to Potential Sterility Breach
05/07/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for Fresenius DELFLEX peritoneal dialysis solutions due to potential bag leaks compromising sterility, affecting more than 80 000 units used in renal care.
The US Food and Drug Administration (FDA) has issued a Class II recall for Fresenius DELFLEX peritoneal dialysis solutions due to potential bag leaks compromising sterility, affecting more than 80 000 units used in renal care.
The US Food and Drug...
05/07/2026
Pharmacy Learning Network
News
Lubricant Eye Drops Under Class II Recall for Sterility Concerns
05/07/2026
Hannah Musick
A class II recall has been issued for FRESHKOTE Lubricant Eye Drops due to sterility assurance concerns, affecting more than 50 000 units used for dry eye relief.
A class II recall has been issued for FRESHKOTE Lubricant Eye Drops due to sterility assurance concerns, affecting more than 50 000 units used for dry eye relief.
A class II recall has been...
05/07/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use